MedTrace Logo

Evaluation of Relative Bioavailability of D-0502 Tablet in Healthy Female Subjects

NCT05226338 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2022-08-08

No results posted yet for this study

Summary

Relative Bioavailability study of D-0502 tablet formulation in healthy female subjects

Conditions

  • Healthy Female Volunteer

Interventions

DRUG

D-0502

Formulation 1 Formulation 2 Formulation 3

Sponsors & Collaborators

  • InventisBio Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-27
Primary Completion
2021-12-23
Completion
2022-05-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05226338 on ClinicalTrials.gov